TABLE 3

Cause analysis of false-positive serum AspLFD results in control group

Patient characteristic or testaMean ± SD (no. of patients with serum LFD result or as indicated), no. (%) of patients with serum LFD result, or as indicatedP valueb
False positive (n = 21)Negative (n = 44)
Characteristics
    Age (yrs)68.7 ± 8.562.7 ± 11.70.0375
    No. of patients male/female14/721/230.189
    Prior pulmonary tuberculosis infection2 (9.5)0 (0)0.101
    COPD1 (4.8)2 (4.5)>0.999
    Non-tuberculosis Mycobacterium infection4 (19)5 (11.4)0.4546
    Interstitial pneumonia6 (28.6)19 (43.2)0.289
    Prior lung surgery0 (0)4 (9)0.306
    Lung cancer1 (4.8)2 (4.5)>0.999
    Cavitary legion10 (47.6)6 (13.6)0.0051
    Bacterial infection (pneumonia, lung abscess)4 (19)5 (11.4)0.443
    Hematological malignancy1 (4.8)4 (9)>0.999
    Diabetes mellitus5 (23.8)8 (18.1)0.7416
    Corticosteroid usage4 (19)16 (36.4)0.25
    Immunosuppressant usage3 (14.3)7 (15.9)>0.999
    Penicillium spp. culture positive in BAL fluid3 (14.3)3 (6.8)0.378
Tests (result)
    BAL fluid AspLFD (positive)6 (28.6)13 (29.5)>0.999
    Serum GM1.27 ± 1.350.6705 ± 0.710.0209
    Serum GM (positive; COI, 1.54)3 (14.3)2 (4.5)0.3181
    BAL fluid GM1.2 ± 2.40.506 ± 1.740.1907
    BAL fluid GM (positive; COI, 0.6)8 (38.1)3 (6.8)0.0033
    Serum BDG (pg/ml)10.6 ± 5.911.8 ± 10.60.6373
    Serum BDG (positive; cutoff, 19.3 pg/ml)2 (9.5)4 (9)>0.999
  • a COPD, chronic obstructive pulmonary disease; BAL, bronchoalveolar lavage; AspLFD, Aspergillus-specific lateral-flow device test; GM, galactomannan; COI, cutoff index; BDG, β-d-glucan.

  • b A P value of <0.05 (Fisher’s exact test or unpaired t test) was considered significant. Values in boldface are significant.